论文部分内容阅读
目的探讨B细胞淋巴瘤蛋白-6(BCL-6)、E盒结合锌指蛋白2(ZEB2)、蛋白酪氨酸磷酸酶基因(PTEN)以及血管内皮生长因子-D(VEGF-D)在乳腺癌组织中的表达情况及其临床意义。方法 95例术前未做化疗的乳腺癌患者(Ⅰ期18例,Ⅱ期34例,Ⅲ期29例,Ⅳ期14例)作为乳腺癌组,60例乳腺良性增生病变患者作为良性病变组。比较两组患者免疫组化检测其BCL-6、ZEB2、PTEN与VEGF-D表达情况。结果乳腺癌组患者BCL-6、ZEB2与VEGF-D表达阳性率分别为56.84%、50.53%、62.11%,高于良性病变组的18.33%、21.67%、15.00%;PTEN表达阳性率为12.63%,低于良性病变组的76.67%,差异均具有统计学意义(P<0.05)。BCL-6、ZEB2与VEGF-D表达阳性率与乳腺癌组病理分期呈正相关(r=0.572、0.431、0.794,P<0.05),PTEN表达阳性率与乳腺癌组病理分期呈负相关(r=-0.353,P<0.05)。结论乳腺癌患者BCL-6、ZEB2与VEGF-D表达升高,PTEN表达降低,对其进行监测,能为其诊断及病情评估提供参考。
Objective To investigate the expression of Bcl-6, ZEB2, PTEN and VEGF-D in breast The expression of cancer and its clinical significance. Methods Ninety-five patients with breast cancer without preoperative chemotherapy (18 in stage Ⅰ, 34 in stage Ⅱ, 29 in stage Ⅲ, and 14 in stage Ⅳ) were selected as the breast cancer group and 60 benign prostatic hyperplasia patients as benign lesions. The expression of BCL-6, ZEB2, PTEN and VEGF-D in the two groups were compared by immunohistochemistry. Results The positive rates of BCL-6, ZEB2 and VEGF-D in breast cancer patients were 56.84%, 50.53% and 62.11% respectively, higher than those in benign lesions 18.33%, 21.67% and 15.00%. The positive rate of PTEN was 12.63% , Which was lower than 76.67% in benign lesion group, the differences were statistically significant (P <0.05). The positive rates of BCL-6, ZEB2 and VEGF-D were positively correlated with the pathological stage of breast cancer (r = 0.572,0.431,0.794, P <0.05). The positive rate of PTEN was negatively correlated with the pathological stage of breast cancer (r = -0.353, P <0.05). Conclusions The expression of BCL-6, ZEB2 and VEGF-D in breast cancer patients is increased, and the expression of PTEN is decreased. The surveillance of BCL-6, ZEB2 and VEGF-D can provide a reference for their diagnosis and assessment of disease.